Phosphonic acid derivatives as inhibitors of the non-mevalonate pathway

Overview

This research focuses on phosphonic acid derivatives designed as inhibitors of the non-mevalonate isoprenoid biosynthesis pathway, specifically targeting the enzyme 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR). The compounds are structural analogs of fosmidomycin, a well-characterized natural antibiotic that potently inhibits DXR. By targeting this pathway, which is absent in humans but essential for many pathogenic bacteria, these derivatives represent a promising strategy for developing novel antimicrobial therapeutics with a reduced likelihood of host toxicity.

Technical specifications

Key features:

• Phosphonic acid derivatives designed as structural analogs of fosmidomycin
• Target: 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), the second rate-limiting enzyme in the non-mevalonate pathway
• Mechanism: inhibition of the reduction and isomerization of DXP to MEP
• Pathway selectivity: the non-mevalonate pathway is present in many pathogenic microorganisms but absent in humans, enabling selective antimicrobial action
• Research-stage small molecule compounds intended for further medicinal chemistry optimization and biological evaluation

Technology readiness level

This is an early-stage research program focused on the design and synthesis of novel phosphonic acid-based DXR inhibitors. The compounds have been designed based on the established pharmacological profile of fosmidomycin but have not yet been described as commercially validated therapeutics. Further validation through enzymatic assays, microbiological testing, and preclinical studies would be required to advance toward drug development.